Last reviewed · How we verify
Docetaxel only
Docetaxel is a microtubule inhibitor that binds to tubulin and prevents microtubule assembly.
Docetaxel is a microtubule inhibitor that binds to tubulin and prevents microtubule assembly. Used for Breast cancer, Non-small cell lung cancer, Prostate cancer.
At a glance
| Generic name | Docetaxel only |
|---|---|
| Sponsor | Samsung Medical Center |
| Drug class | Taxane |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This prevents cell division and leads to cell death, making it effective in treating various cancers.
Approved indications
- Breast cancer
- Non-small cell lung cancer
- Prostate cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (PHASE2)
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) (PHASE1, PHASE2)
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) (PHASE1, PHASE2)
- Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery (PHASE2)
- Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (PHASE2)
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel only CI brief — competitive landscape report
- Docetaxel only updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI